Dermatology

Latest drug update covers Pembrolizumab for IV injection (Keytruda®, Merck & Co.), Guselkumab for SC injection (Tremfya®, MorphoSys/Janssen), Dupilumub for SC injection (Dupixent®, Regeneron), and Risankizumab for SC injection (Skyrizi™, AbbVie).

Glycopyrronium tosylate (Qbrexza), a topical anticholinergic therapy, has been shown to be effective in the treatment of primary axillary hyperhidrosis.

Crisaborole represents a novel and efficacious therapeutic approach for the treatment of mild to moderate Atopic Dermatitis and demonstrates early and continued decrease in pruritus, which improves quality of life and reduces the potential risk of infection and scarring.

A list of skin treatments introduced in 2018, categorized by type/class of therapy. The content primarily focuses on approvals issued by US and Canadian drug regulatory agencies and is sourced from both regulatory and industry news releases.

Latest drug update covers Pembrolizumab, Oral JAK + SYK dual inhibitor, Lidocaine 7% + tetracaine 7% local anesthetic cream and PrabotulinumtoxinA-xvfs.

Primary focal hyperhidrosis afflicts a significant number of patients in the United States and greatly impacts their quality of life. Treatment decisions should take into consideration disease location, severity and patient preference.

There are many new immunotherapeutics that have been approved or are in clinical and pre-clinical trials to expand our arsenal in the treatment of melanoma and other previously difficult to treat malignancies.

Update on Dalbavancin hydrochloride for IV infusion (Xydalba™), Omadacycline for IV and oral use (Nuzyra™), Tildrakizumab-asmn for SC injection (Ilumya™), Adalimumab-adaz for SC injection (Hyrimoz™) and other new drugs and treatments.

Articles are indexed by drug names, trade names and disease terms. Bold entries refer to major references. Use the main navigation (A, B, C..) to navigate through this index and use the reference links (i.e. 4:5-9) to see the sources.

Learn about cannabinoids influence on skin growth control, homeostasis, melanoma, acne, pruritus, inflammation, atopic dermatitis, and other skin conditions.

Afamelanotide, an α-melanocyte stimulating hormone analogue, has become an emerging therapeutic option for a variety of skin conditions previously refractory to other treatments.

Update on PrabotulinumtoxinA, Tretinoin 0.05% lotion, Cemiplimab-rwlc, Autologous fibroblast gene therapy, Oral JAK3 inhibitor, Halobetasol propionate 0.01% lotion, Sarecycline hydrochloride tablets and HPV 9-valent vaccine.

The Pigmented Lesion Assay (PLA) is a gene expression test that helps rule out melanoma and has the potential to reduce the need for surgical biopsies of atypical pigmented skin lesions.

Chronic pruritus remains a difficult condition to treat with many non-specific therapeutic options. Recent scientific discoveries have elucidated the physiology associated with pruritus.

Updates on Binimetinib + Encorafenib (Mektovi® + Braftovi®), Crisaborole 2% ointment (Eucrisa™), Glycopyrronium tosylate 2.4% cloth (Qbrexza™), Secukinumab for SC injection (Consentyx®), Tecovirimat capsule (Tpoxx), Diacerein 1% ointment (CCP-020), Migalastat capsule (Galafold™), Mogamulizumabkpkc for IV use (Poteligeo®)

Alitretinoin is an oral retinoid which has proven efficacy and safety in the treatment of chronic hand dermatitis through randomized controlled trials.

Most people with mild-to-moderate psoriasis manage their disease with topical therapies. However, adherence to topical treatment remains a challenge.. Read about new topical therapeutic options.

Update on Dabrafenib + trametinib in combination (Tafinlar®+Mekinist®), Certolizumab pegol for SC injection (Cimzia®), Ubidecarenone injectable nanosuspension (BPM 31510), Diacerein 1% ointment (CCP-020), Ixekizumab for SC injection (Taltz®), Hyaluronic acid (HA) dermal filler (Restylane® Lyft®), and Rituximab for IV use (Rituxan®).

Urticaria is a common, mast-cell-driven disease, characterized clinically by the development of wheals, angioedema, or both. A large body of data has demonstrated that omalizumab, a biologic agent, is safe and effective in the treatment of H1- antihistamine refractory urticaria and should be considered as a third-line agent, with cyclosporin A reserved for fourth-line therapy.

The class of medications known as Janus kinase inhibitors block cytokine-mediated signaling via the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway, which plays an important role in immunoregulation and normal cell growth.

Update on Drugs & Devices May and June 2018: Tildrakizumab-asmn for SC injection Ilumya™, Lidocaine topical system 1.8% for postherpetic neuralgia ZTlido™, Secukinumab for SC injection Cosentyx®, Vaginal gel for prevention of urogenital chlamydia Amphora®.

Interleukin (IL)-17 is important in the pathophysiology of psoriasis and has proven to be an effective therapeutic target. As brodalumab enters the marketplace, a review of this important biologic, its safety profile, and discussion of possible adverse effects is in order.

A comprehensive review of Fabry Disease. Typical presentations, other signs and symptoms, differential diagnosis, as well as treatment options are discussed.

A look back at skin treatments introduced in 2017 for the following type/class of therapy: Antibiotic agents, anti-cancer agents, atopic dermatitis, dermal fillers, fabry disease, hereditary angioedema, herpes zoster, hidradenitis suppurativa, psoriasis, psoriatic arthritis, rosacea...

Update on Drugs & Devices March and April 2018: Hydrogen peroxide topical solution Eskata™, Mepolizumab for SC injection Nucala® GSK, Brentuximab vedotin for IV use Adcetris®, CoolSculpting®, (PDF) patch DeScribe® PFD Patch, Adhesive patch for melanoma detection Pigmented Lesions Assay (PLA)

An increasing body of research indicates that dietary change may serve as a component of therapy for certain skin conditions. This includes conditions such as acne, atopic dermatitis, aging skin, psoriasis, and rosacea. This article takes a high level overview of the role that diet may play in these conditions.

Recent advances in the treatment of hereditary angioedema, particularly in the last decade has been promising. This paper reviews the mechanisms, efficacy, and adverse reactions associated with these new treatment medications. 

Update on drugs includes Onabotulinum-toxinA for injection (Botox® Cosmetic), Hyaluronic acid dermal filler (Restylane® Silk), Ustekinumab for SC injection (Stelara®), Golimumab for IV infusion (RSimponi Aria®), Herpes zoster vaccine (non-live recombinant, AS01B adjuvanted) suspension for IM injection (Shingrix), Brentuximab vedotin for IV infusion (Adcetris®)

Despite a rising prevalence, effective and safe therapeutics for patients with moderate-to-severe AD are limited due to toxicity and side effects. Dupilumab, an interleukin (IL)-4 and IL-13 antagonist that limits type 2 T helper (Th2) driven inflammatory activity, is a promising therapeutic option.

Use of azelaic acid was associated with a significant reduction in inflammatory lesions, which persisted beyond the active treatment phase. Overall, azelaic acid 15% gel is an appropriate initial topical therapy for the treatment of moderate facial rosacea.

November-December 2017 Update on drugs includes Adalimumab-adbm for SC injection Cyltezo™, Adalimumab biosimilar Imraldi®, Cemiplimab REGN2810, Oral migalastat Galafold™, and Secnidazole oral granules Solosec™

Recent studies have demonstrated the role of Vitamin B Derivative (Nicotinamide), in both topical and oral forms, as a chemopreventive agent against skin cancer.

Epidermal growth factor receptor (EGFR) inhibitors are part of an emerging class of anticancer medicines known as "targeted therapy". Adverse effects of such treatments are thought to be less severe, but can still be significant.

September-October 2017 Update on drugs include Isopropyl myristate solution Resultz®, Delafloxacin oral and IV formulations Baxdela™, Plasma-derived concentrate of C1 esterase inhibitor SC (human) Haegarda®, Oral dimethyl fumarate Skilarence®, Abatacept for IV or SC injection Orencia®, Consentyx®, Tremfya™, Yervoy® and Benlysta®.

Secukinumab demonstrates rapid and robust clinical improvement accompanied by a favorable short- term safety profile. The results of the phase III trials continue to reinforce the theory that the IL-17 pathway is an essential target in psoriasis and psoriatic arthritis treatment.

Hepatitis B virus (HBV) and hepatitis C virus (HCV) potentially impact the clinician's ability to manage patients with immunosuppressive medications such as biological therapy. In light of recent literature reviews, patients with HBV and HCV should be referred to a hepatologist.

This drug update covers Infliximab-abda for IV infusion Renflexis®, Ozenoxacin 1% cream Ozanex™, Standardized allergen extract of house dust mites sublingual tablet Acarizax®, Doxycycline hyclate immediate release tablet, and UVB Phototherapy SystemClarify™ Home Light Therapy System.

Psoriasis is a chronic condition that affects the well-being and quality of life of patients. The disease is associated with an increased risk of depression and suicidality, which may not be fully understood by the general population.

A triad approach to the treatment of acne and rosacea has been recommended. This integrated management approach includes patient education, selection of therapeutic agents, and initiation of an appropriate skin care regime. Appropriate skin care recommendations for patients with acne and rosacea will be discussed.

Update on Dupilumab for SC injection Dupixent®, Dupilumab for SC injection, Avelumab for IV injection Bavencio®, Hyaluronic acidbased injectable dermal filler Juvéderm®, Biosimilar to adalimumab for SC injection Amgevita™ Vollure™ XC, Adalimumab for SC injection Humira®, and Amgevita™.